

Patient Selection for OIT

Tom Chacko and Jean Ly



Diagnosis: History

- Clear IgE-mediated symptoms attributable to the allergen ingestion
- Consistent sensitization to the allergen
- Oral Food Challenge (OFC) is not required unless:
 - To clarify diagnosis with ambiguous cases
 - Establish baseline threshold pretherapy
 - Shared Decision Making



I ADLE IV	ILEIGIUN 3	citteria iu	recommended	challenge	location
-----------	------------	-------------	-------------	-----------	----------


2	Best clinical judgment (consider for home)	Home	Clinic	Infusion center	Best clinical judgment (consider for CAT/CR)	Not recommended
Egg	a de la constanción d	sIgE \leq 0.35 kU/L SPT \leq 5 mm	sIgE > 0.35 and ≤ 2 kU/L SPT > 5 and ≤ 7 mm	sIgE > 2 and ≤ 6 kU/L SPT > 7 and ≤ 8 mm	sIgE > 6 and \leq 10 kU/L SPT > 8 and \leq 10 mm	sIgE > 10 kU/L SPT >10 mm
Baked egg		EW sIgE \leq 1 kU/L OVM sIgE \leq 1 kU/L SPT \leq 10 mm	$\begin{array}{l} EW \ sIgE > 1 \ and \leq 10 \ kU/L \\ OVM \ sIgE > 1 \ and \leq 10 \ kU/L \\ SPT > 10 \ and \leq 25 \ mm \end{array}$	EW sIgE >10 and \leq 20 kU/L OVM sIgE >10 and \leq 15 kU/L SPT > 25 and \leq 35 mm	EW sIgE > 20 and ≤ 40 kU/L OVM sIgE >15 and ≤ 35 kU/L SPT > 35 mm	EW sIgE > 40 kU/L OVM sIgE > 35 kU/L
Milk		$sIgE \le 0.5 kU/L$ SPT neg (0)	sIgE > 0.5 and \leq 2 kU/L SPT > 0 and \leq 8 mm	sIgE > 2 and ≤ 5 kU/L SPT > 8 and ≤ 10 mm	sIgE > 5 and < 15 kU/L SPT > 10 and ≤ 12 mm	$sIgE \ge 15 kU/L$ SPT > 12 mm
Baked milk		$sIgE \le 1 kU/L$ SPT $\le 10 mm$	sIgE > 1 and ≤ 15 kU/L SPT > 10 and ≤ 15 mm	sIgE >15 kU/L and \leq 20 kU/L SPT > 15 mm and \leq 20 mm	sIgE > 20 and ≤ 40 kU/L SPT > 20 and ≤ 35 mm	sIgE > 40 kU/L SPT > 35 mm
Peanut	sIgE \leq 0.35 kU/L SPT neg (0) Ara h2 \leq 0.35 kU/L		sIgE > 0.35 and \leq 0.7 kU/L SPT > 0 and \leq 5 mm Ara h2 \leq 0.35 kU/L	sIgE > 0.7 and ≤ 1 kU/L SPT > 5 and < 8 mm Ara h2 > 0.35 and ≤ 1 kU/L	sIgE > 1 and < 15 kU/L SPT \ge 8 and < 10 mm Ara h2 > 1 and < 2 kU/L	sIgE \geq 15 kU/L SPT \geq 10 mm Ara h2 \geq 2 kU/L
Tree nut	sIgE \leq 0.35 kU/L SPT neg (0) mm		$\begin{array}{l} sIgE > 0.35 \mbox{ and } \leq 0.5 \mbox{ kU/L} \\ SPT > 0 \mbox{ and } \leq 5 \mbox{ mm} \end{array}$	$\begin{array}{l} sIgE > 0.5 \mbox{ and } \leq 3 \mbox{ kU/L} \\ SPT > 5 \mbox{ and } \leq 6 \mbox{ mm} \end{array}$	sIgE > 3 and <18 kU/L SPT > 6 and < 8 mm	$ sIgE \geq 18 \ kU/L \\ SPT \geq 8 \ mm $

Boston Children's Article (JACI in Practice 2017) with cut off points on when not to challenge certain foods.

Co-Morbidities Risk Assessment

<u>High Risk</u>

- H/o lifethreatening anaphylaxis
- Uncontrolled Asthma
- Pregnancy (build up)
- Type of food (egg/milk -higher risk??



Moderate Risk

- Eosinophilic GI disorders
- Chronic Urticaria
- Mastocytosis/mast cell disorder
- Beta-blocker or ACE- Inhibitor
- Chronic conditions that may lower allergen thresholds

Co-Morbidities Risk Assessment

Nonmedical

- Excessive anxiety
- Taste aversion
- Non-compliance
- Scared of epinephrine
- Distance from home to hospital
- Language Barrier
- Non collaborative family dynamics
- Lack of schedule flexibility


Not Contraindications

- Controlled Asthma
- Mild/moderate anaphylaxis
- Multi food allergies
- High specific food IgE


Food Allergy and Balance




- Younger ages may have better outcomes + fewer systemic reactions
- OIT for all ages
- What is the natural resolution of the Food Allergy (milk or egg)



Wasserman JACI Pract 2019



Each year of delay after age 5 decreases the likelihood of success by 17%



Early Peanut OIT is Safe and Highly Effective - Vickery

37 toddlers Randomized 1:1 to <u>1 or 10 peanuts</u>

Build up: 42 weeks, 21 visits (~97% reached target)

Maintenance: median ~2.5 yr, (at least 12 mon, pslgE <15, ST <8mm)

Eligible for 16 peanut challenge:

81% passed "desensitized"

1 month no peanut, 16 peanut re-challenge:

78% sustained unresponsiveness

Reactions: 85% mild, 15% mod., none severe

No differences in immunologic responses between groups

First Real-World Safety Analysis/Effectiveness of Preschool Peanut OIT

- 270 Canadian preschoolers
 - Build up to target dose 1 peanut
 - 90% Reached target
 - 68% Had OIT reactions- most mild/moderate, 1 severe
 - 11 Received epi (4%)

- Follow up: 1 year on 1 peanut daily
 - 79% Passed 13 peanuts (Vickery 81%)
 - 98% Passed >3 peanuts



First Real-World Safety Analysis/Effectiveness of Preschool Peanut OIT

2022 infant (<12 months) analysis:

- Infants: fewer grade 2+ reactions during baseline OFC or buildup
 - (33.9% vs 53.7%; P .002)
- Build up: One infant (1.60%) received epi
- None of the infant dropouts needed epi
- Infants had no grade 2+reactions during follow-up OFC
 - 7.70% of NI-preschoolers did



Preschool Peanut vs Multi-Food OIT

<=60 months old	N	Age (median)	Day 1 reaction	Day 1 Epi	Maintenance < 1 year	Maintenance	Epi reactions	Escalating
Peanut	58	40 months	9 (16%)	1	40 (69%)	51 (88%)	5 (9%)	0
Multi-food	35	43 months	5 (14%)	0	21 (60%)	28 (80%)	3 (9%)	0

Data: Windom Allergy AAAAI Abstract 2022

How I Select Preschool OIT Candidates

- Are they likely to outgrow peanut allergy?
 - Severity of reaction
 - Severity of eczema
 - Testing 95% PPV persistent allergy:
 - 1 yo 13 mm wheal, slgE 5
 - 2 yo 6 mm wheal, sIgE 3
 - Resolution: Decrease in testing



Proactive Parents/Anxiety/Shared Decision



<u>Adherence</u>

- OIT discontinuations occur most commonly during build up
 - Systemic reactions
 - Gastrointestinal side effects
 - Taste aversion
- Patients' goals and preferences should be reassessed periodically

Unmet Need - Long Term Follow-Up

Adherence:

	SCIT	SLIT	ΟΙΤ
2 years	61%	33%	
3 years	36%	14%	
3-8 years			50-92%

5 Year Early Peanut OIT Follow Up- Vickery

- 29 responders to phone survey
 - 93% continued to eat peanut
 - 62% regularly carried epinephrine devices
 - 59% no longer saw an allergist
 - 31% chronic GI complaints (2 EoE: 1 egg, 1 peanut: 3%)

References

- Wasserman, et al. An Approach to the Office-Based Practice of Food Oral Immunotherapy <u>https://doi.org/10.1016/j.jaip.2021.02.046</u>
- Leonard, Integrating oral immunotherapy into clinical practice. <u>https://doi.org/10.1016/j.jaci.2020.11.011</u>
- Vickery, JACI 2017 Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective
- Simberloff et al, JACI Practice JACI Practice 2017, Implementation of a Standard Clinical Assessment and Management Plan (SCAMP) for Food Challenges
- Vickery, Clin Exp Allergy 2019, High and low dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children
- Vickery, JACI Pract 2021, Five-year follow-up of early intervention peanut oral immunotherapy
- Soller, JACI Pract 2019, First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy
- Soller, JACI Pract 2020, First Real-World Effectiveness Analysis of Preschool Peanut Oral Immunotherapy
- Soller JACI Pract 2022 Real-world peanut OIT in infants may be safer than non-infant preschool OIT and equally effective
- Shaker, JACI Pract 2021, The Cost-Effectiveness of Preschool Peanut Oral Immunotherapy in the Real-World Setting
- Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients. JACI Pract Feb 2019